Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06974617
NA
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Sponsor: Cairo University
View on ClinicalTrials.gov
Summary
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Official title: Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2025-05-15
Completion Date
2025-10-01
Last Updated
2025-05-16
Healthy Volunteers
No
Interventions
DRUG
Sphenopalatine block
Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
DRUG
Botulinum Toxin Type A
Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
Locations (1)
Cairo University
Cairo, Egypt